Spyre Therapeutics reported early Phase 2 data for SPY001 in ulcerative colitis, meeting the study’s primary goal and supporting further development as the company aims to compete with entrenched biologic options. In the SKYLINE trial, Spyre said SPY001 produced a 9.2-point decrease in disease activity index after treatment and approximately 40% of subjects reached remission after 12 weeks. The program targets the alpha4beta7 inflammation pathway, an approach intended to reduce gut inflammation. The first batch of results adds to the growing competitive landscape in inflammatory bowel disease, where pipeline differentiation hinges on response durability, safety, and proportion of responders across early and later lines of therapy.